Advancing mRNA Medicines to Fight and Prevent Disease
Moderna is driven by our mission to deliver on the promise of mRNA science to create a new generation of transformative medicines for patients. We are currently advancing mRNA clinical studies on our development candidates to address serious unmet needs across several therapeutic areas and multiple diseases. Clinical (human) trials are now underway for several of our investigational mRNA vaccines and therapeutics that may have the potential to treat or prevent rare diseases, viruses and cancers.
Moderna is actively recruiting participants to join our clinical trials by evaluating investigational mRNA therapies and vaccines for the treatment or prevention of Methylmalonic Acidemia (MMA), Cytomegalovirus (CMV), cancers and other diseases. We have provided links to our clinical trial listings on www.clinicaltrials.gov, where you can find more information, including details on eligibility criteria and clinical trial locations for each study. You can also view our full list of mRNA clinical trials below.
Below is a list of clinical trials for which Moderna is actively recruiting participants. We have provided links to the study listings on www.clinicaltrials.gov, where you can find more information, including details on eligibility criteria and clinical trial locations.
Actively Recruiting mRNA Clinical Trials
mRNA Prophylactic Vaccines
Disease | Program | Study Phase | Study Focus | More Info |
---|---|---|---|---|
COVID-19 |
mRNA-1273 |
Phase 2/3 | Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19 (TeenCove) |
Learn more about this study |
Cytomegalovirus (CMV) |
mRNA-1647 |
Phase 2 | Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus Vaccine mRNA-1647 in Healthy Adults |
Learn more about this study |
Zika |
mRNA-1893 |
Phase 1 | Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults | clinicaltrials.gov |
mRNA Cancer Vaccines
Disease | Program | Study Phase | Study Focus | More Info |
---|---|---|---|---|
Solid tumors |
mRNA-4157 |
Phase 1 | Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors (KEYNOTE-603) | clinicaltrials.gov |
Melanoma |
mRNA-4157 |
Phase 2 | An Efficacy Study of Adjuvant Treatment with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Patients With High-Risk Melanoma (KEYNOTE-942) |
Learn more about this study |
mRNA Intratumoral Immuno-Oncology
Disease | Program | Study Phase | Study Focus | More Info |
---|---|---|---|---|
Advanced / metastatic solid tumors or lymphoma |
mRNA-2416 |
Phase 1 | Dose Escalation Study of mRNA-2416 for Intratumoral Injection to Patients with Advanced Malignancies | clinicaltrials.gov |
Relapsed/Refractory solid tumors malignancies or lymphoma |
mRNA-2752 |
Phase 1 | Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Patients with Advanced Malignancies | clinicaltrials.gov |
mRNA Systemic Secreted & Cell Surface Therapeutics
Disease | Program | Study Phase | Study Focus | More Info |
---|---|---|---|---|
Chikungunya virus |
mRNA-1944 |
Phase 1 | Safety, tolerability, pharmacokinetics and pharmacodynamics of mRNA-1944 in healthy adults | clinicaltrials.gov |
mRNA Systemic Intracellular Therapeutics
Disease | Program | Study Phase | Study Focus | More Info |
---|---|---|---|---|
Methylmalonic Acidemia |
mRNA-3704 |
Phase 1/2 | Open Label Study of mRNA-3704 in Patients With Isolated Methylmalonic Acidemia | clinicaltrials.gov |
Methylmalonic Acidemia, Propionic Acidemia |
mRNA-3704 |
Natural History Study | Longitudinal, exploratory, natural history study of patients with MMA due to mut deficiency and PA |
clinicaltrials.gov |